Cargando…

Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications

BACKGROUND: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are chronic immune-mediated inflammatory diseases (IMIDs) associated with cardiovascular (CV) disease. High-sensitivity C-reactive protein (hsCRP) and, more recently, the neutrophil–lymphocyte ratio (NLR) are impor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merola, Joseph F., McInnes, Iain B., Deodhar, Atul A., Dey, Amit K., Adamstein, Nicholas H., Quebe-Fehling, Erhard, Aassi, Maher, Peine, Michael, Mehta, Nehal N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127026/ https://www.ncbi.nlm.nih.gov/pubmed/35305260 http://dx.doi.org/10.1007/s40744-022-00434-z

Ejemplares similares

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
por: Schreiber, Stefan, et al.
Publicado: (2019)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
por: Braun, Jürgen, et al.
Publicado: (2021)

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
por: van der Horst-Bruinsma, Irene, et al.
Publicado: (2021)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data
por: Deodhar, A., et al.
Publicado: (2019)

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
por: Hampton, P., et al.
Publicado: (2021)

34346 Pooled safety analysis of respiratory tract infections, including COVID-19, in psoriasis patients treated with secukinumab
por: Schulze-Koops, Hendrik, et al.
Publicado: (2022)

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies
por: Deodhar, Atul A., et al.
Publicado: (2020)

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
por: GOTTLIEB, Alice B., et al.
Publicado: (2022)

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
por: Stingeni, Luca, et al.
Publicado: (2023)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
por: Pournara, Effie, et al.
Publicado: (2021)

Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
por: McInnes, Iain B, et al.
Publicado: (2022)

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
por: McInnes, Iain B, et al.
Publicado: (2017)

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study
por: McInnes, Iain B., et al.
Publicado: (2018)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
por: Nash, Peter, et al.
Publicado: (2018)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies
por: McGonagle, Dennis, et al.
Publicado: (2023)

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study
por: Gottlieb, A.B., et al.
Publicado: (2021)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study
por: Tahir, Hasan, et al.
Publicado: (2017)

Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
por: Deodhar, Atul A., et al.
Publicado: (2016)

Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
por: Talamonti, Marina, et al.
Publicado: (2023)

Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a post-hoc analysis of pooled data from three phase 3 trials with secukinumab
por: Dehlin, Mats, et al.
Publicado: (2021)

Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
por: Tseng, Jui-Cheng, et al.
Publicado: (2020)

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
por: TALAMONTI, Marina, et al.
Publicado: (2021)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
por: Kiltz, Uta, et al.
Publicado: (2020)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies
por: Körber, Andreas, et al.
Publicado: (2018)

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
por: Adsit, Sandra, et al.
Publicado: (2017)

Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
por: Sticherling, Michael, et al.
Publicado: (2023)

Leukotrienes, mast cells, and T cells
por: McInnes, Iain B
Publicado: (2003)

Introduction
por: McInnes, Iain B
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_ith4vdu88vjt85cg950dqnf8r1